Technologies
Ivermectin and COVID-19: Why poison centers are getting calls about this controversial drug
Is this a miracle pill or a sham?
Since the start of the COVID-19 pandemic, some medical professionals have reviewed already available drugs to see if they could be used as effective treatments. Ivermectin, an anti-parasitic, was administered to some patients across the globe, with seemingly positive effects. However, more studies show it has little to no effect when it comes to treating COVID-19. There’s also been an increase in calls to poison centers by people who are taking ivermectin intended for animals.
On one side, there are doctors who say ivermectin could help end the pandemic if used globally. On the other are public health officials who have reviewed the data and say the drug’s effectiveness against COVID-19 isn’t conclusive.
Here’s everything you need to know about ivermectin and its use for COVID-19.
What is ivermectin?
Ivermectin is an anti-parasitic medicine «that works by altering cellular channels,» said Dr. Soumi Eachempati, CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College. The drug inhibits some viruses from infecting cells, thus preventing the virus from spreading. Ivermectin is usually given to treat parasitic infections like lice and Strongyloides, according to Eachempati.
Scientists at pharmaceuticals giant Merck discovered ivermectin in 1975 and began to use it to treat scabies, river blindness and other parasitic diseases carried by worms and lice starting in 1981. It’s on the World Health Organization’s list of essential medicines for a basic health care system. More than 250 million people take the drug across the globe each year, and it’s effective for animals as well.
The drug is considered safe when taken in appropriate dosages. Side effects for the ivermectin vary depending on whether it’s taken orally to treat intestinal infections or topically for skin infections. Oral tablets can cause drowsiness, nausea, vomiting and, in very rare cases, an increase in heart rate and seizures. Side effects for the topical ivermectin can include skin rash and irritation, while dry skin and stinging pain are severe and rare.
Can ivermectin be used to cure COVID-19?
This is where things get complicated. Public health agencies, including the Federal Drug Administration, the National Institutes of Health and the World Health Organization, don’t suggest ivermectin’s use to treat COVID-19. They cite the lack of data from large, randomized trials confirming the drug’s effectiveness to treat the disease.
Doctors who cited multiple smaller studies and firsthand experience say otherwise. They claim ivermectin does work to prevent people from developing symptoms from COVID-19 and can shorten recovery time for those already infected.
What do the public health agencies say about ivermectin use for COVID-19 treatment?
The FDA said in March it hasn’t approved the use of ivermectin to treat COVID-19. It warned that large doses of the drug are «dangerous and can cause serious harm.» The agency also advised against human use of ivermectin produced for animals, such as cows and horses, as the doses aren’t the same and could contain ingredients intended only for animals.
A growing number of people have been taking ivermectin for animals as word’s spread on social media about its possible use against COVID-19. This has resulted in some people calling state poison centers after taking the drug, since the medication is intended for animals. On Aug. 20, the Mississippi State Department of Health sent out an alert regarding the number of calls its poison center received, with 70% related to the «ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers.»
In April, the FDA reaffirmed in a post on its website that ivermectin isn’t approved to treat COVID-19 nor has it been given emergency use authorization.
The NIH said in February there was insufficient data to «recommend either for or against the use of ivermectin for the treatment of COVID-19.» It did say lab tests found the drug stopped the reproduction of the SARS-CoV-2 virus that cause the disease. However, to be effective, the dosages would need to be «100-fold higher than those approved for use in humans.»
While some clinical studies showed ivermectin to have no benefit, the NIH said others saw a lower mortality rate among patients. However, those studies were incomplete or had methodological limitations such as small sample sizes or patients receiving additional medicine along with ivermectin, according to the NIH.
The WHO said in March the current evidence on the use of ivermectin for treatment of COVID-19 was «inconclusive.»
A doctor in Arkansas who prescribed the drug to patients is under investigation by the state medical board, according to a report from CNN. He reportedly gave ivermectin prescriptions to prisoners at the county jail where he was contracted to provide medical services.
Who says ivermectin is a treatment, and what information do they have?
Ivermectin’s potential use as a COVID-19 therapeutic made headway last December during a Senate Homeland Security Committee meeting called Focus on Early Treatment of COVID-19. Dr. Pierre Kory, a pulmonary and critical care specialist, testified about the drug’s usage for treatment of the disease.
«Ivermectin is highly safe, widely available, and low cost,» Kory said in the Senate meeting. «We now have data from over 20 well-designed clinical studies, 10 of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. These data show that ivermectin is effectively a ‘miracle drug’ against COVID-19.»
During his testimony, Kory referred to a paper he authored — Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 — that was published in the May edition of the American Journal of Therapeutics.
The paper was also included in the Frontiers of Pharmacology journal in January but was then removed in March. Dr. Frederick Fenter, chief executive editor of the journal, said the paper was removed due to «strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.» Fender also said the authors promoted their own specific ivermectin-based treatment, which goes against editorial policies.
A study listed in Kory’s paper involved giving ivermectin to 234 uninfected health care workers in Argentina and found those who received the drug were far less likely to be diagnosed with COVID. For mildly ill patients, an Iraq study saw a quicker recovery time.
There are also studies that show otherwise. A clinical trial of 476 patients found ivermectin didn’t improve the recovery time in patients who had COVID-19. A review of 10 random clinical trials, with more than 1,000 participants, also didn’t find improvements with ivermectin. One Egyptian study claimed to show positive results, but it’s since been redacted over ethical concerns. Another study, of 1,500 patients, found that ivermectin had «no effect whatsoever.»
Merck, the company that discovered ivermectin, released a statement in February saying there was «no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies» and «no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease.» It also cited a lack of safety data from major studies.
Why is there controversy over ivermectin?
The debate about ivermectin’s usage to treat COVID-19 has gone from the hospital to social media, exacerbating the discourse as well as the vitriol. While those in support of the drug appear to want an end to the pandemic, their arguments in favor of ivermectin have become fodder for anti-vaxxers and conspiracy theorists.
Groups that have spread misinformation about COVID-19 throughout the pandemic latched onto ivermectin’s usage following Kory’s Senate testimony. Anti-vax groups on Telegram share misinformation about the vaccine while asking where they can buy the drug. Rumble, an alternative video platform to YouTube, has pages of videos falsely saying vaccines are ineffective while advising people to also take ivermectin.
Anti-vax posts and videos can also be found on YouTube, Facebook and Twitter, although the companies are attempting to take these posts down or make them harder to find.
Kory was a guest on the Dark Horse Podcast hosted by Bret Weinstein, a former professor at Evergreen State College, on June 1 to talk about ivermectin. That video was eventually demonetized on YouTube and Weinstein’s channel received a strike, which prevented him from posting content for one week and could lead to its removal if he receives two more strikes within 90 days.
YouTube says its actions on Weinstein’s videos were part of its policies.
«While we welcome open discussions of potential treatments and clinical trials related to COVID-19 on YouTube, based on guidance from the CDC, FDA and other local health authorities, we don’t currently allow content that recommends ivermectin as an effective treatment or prevention method for the virus,» said Ivy Choi, a YouTube spokesperson. «We craft our policies to prevent the risk of egregious real-world harm, and update them as official guidance evolves. We do allow exceptions to our policy about ivermectin, including content that also gives viewers the full context of the FDA’s current position.»
Because of YouTube’s decision, the controversy over ivermectin grew and became tied to what some claim to be «big tech censorship.»
What is required for ivermectin to get approved for COVID-19 treatment?
For the public health agencies, it’s going to come down to the results of large clinical studies being conducted around the world.
«In the UK, it was announced that ivermectin will be added to the Principle Trial, a large clinical study designed to assess potential COVID therapies for non-hospitalized therapies for patients at higher risk for severe disease,» said Dr. David Shafran, head of pediatrics at telehealth app K Health. «This should demonstrate more definitively the efficacy of ivermectin in early-stage COVID infections. Fingers crossed because it’s a cheap medication with a good safety profile. It would be great to add this to the armament of medication to fight COVID.»
The Oxford University Principle Trial has more than 5,000 participants and will give a three-day course of oral ivermectin treatment to individuals randomly and compare their results to individuals who will receive standard care.
In the US, the NIH is evaluating therapeutics for COVID-19 with its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol. ivermectin was added in phase three of ACTIV-6, which will test the effectiveness of repurposed drugs.
«The ACTIV prioritization group, trial team and trial oversight groups continuously track new data on any agent we are studying in our trials and evaluate that data for how it might influence our testing of that agent and the safety/well being of the participants in the trial,» said Dr. Sarah Dunsmore, a program director at the National Center for Advancing Translational Sciences that is part of the NIH.
What’s unclear is how long the whole process will take. The studies need time to be completed, and then the agencies will require additional time to come up with decisions based on the data.
Technologies
Today’s NYT Connections Hints, Answers and Help for Feb. 18, #983
Here are some hints and the answers for the NYT Connections puzzle for Feb. 18 #983.
Looking for the most recent Connections answers? Click here for today’s Connections hints, as well as our daily answers and hints for The New York Times Mini Crossword, Wordle, Connections: Sports Edition and Strands puzzles.
Today’s NYT Connections puzzle was great fun for me, as I’m the co-author of two pop-culture encyclopedias, one about the 1970s, and 1980s and the other about the 1990s. Two of the categories are retro-themed! Read on for clues and today’s Connections answers.
The Times has a Connections Bot, like the one for Wordle. Go there after you play to receive a numeric score and to have the program analyze your answers. Players who are registered with the Times Games section can now nerd out by following their progress, including the number of puzzles completed, win rate, number of times they nabbed a perfect score and their win streak.
Read more: Hints, Tips and Strategies to Help You Win at NYT Connections Every Time
Hints for today’s Connections groups
Here are four hints for the groupings in today’s Connections puzzle, ranked from the easiest yellow group to the tough (and sometimes bizarre) purple group.
Yellow group hint: Farrah hair.
Green group hint: Totally tubular!
Blue group hint: Bock-bock!
Purple group hint: Can refer to a dairy product or a cosmetic.
Answers for today’s Connections groups
Yellow group: Retro hair directives.
Green group: Retro slang for cool.
Blue group: Chicken descriptors.
Purple group: ____ cream.
Read more: Wordle Cheat Sheet: Here Are the Most Popular Letters Used in English Words
What are today’s Connections answers?
The yellow words in today’s Connections
The theme is retro hair directives. The four answers are crimp, curl, feather and tease.
The green words in today’s Connections
The theme is retro slang for cool. The four answers are bad, fly, rad and wicked.
The blue words in today’s Connections
The theme is chicken descriptors. The four answers are bantam, crested, free-range and leghorn.
The purple words in today’s Connections
The theme is ____ cream. The four answers are heavy, shaving, sour and topical.
Technologies
Today’s Wordle Hints, Answer and Help for Feb. 18, #1705
Here are hints and the answer for today’s Wordle for Feb. 18, No. 1,705.
Looking for the most recent Wordle answer? Click here for today’s Wordle hints, as well as our daily answers and hints for The New York Times Mini Crossword, Connections, Connections: Sports Edition and Strands puzzles.
Today’s Wordle answer is a word I thought I’d seen in Wordle before, but I guess not. The letters aren’t super common, so it may take a few guesses. If you need a new starter word, check out our list of which letters show up the most in English words. If you need hints and the answer, read on.
Read more: New Study Reveals Wordle’s Top 10 Toughest Words of 2025
Today’s Wordle hints
Before we show you today’s Wordle answer, we’ll give you some hints. If you don’t want a spoiler, look away now.
Wordle hint No. 1: Repeats
Today’s Wordle answer has no repeated letters.
Wordle hint No. 2: Vowels
Today’s Wordle answer has two vowels.
Wordle hint No. 3: First letter
Today’s Wordle answer begins with M.
Wordle hint No. 4: Last letter
Today’s Wordle answer ends with L.
Wordle hint No. 5: Meaning
Today’s Wordle answer can refer to an important or powerful person.
TODAY’S WORDLE ANSWER
Today’s Wordle answer is MOGUL.
Yesterday’s Wordle answer
Yesterday’s Wordle answer, Feb. 17, No. 1704 was SQUAD.
Recent Wordle answers
Feb. 13, No. 1700: MOOCH
Feb. 14, No. 1701: BLOOM
Feb. 15, No. 1702: SKULL
Feb. 16, No. 1703: ROOST
Technologies
Samsung’s One UI Code Hints at Existence of ‘Wide’ Galaxy Z Fold
The company’s latest Android application packages, spotted by a leaker online, include references to animations for the rumored phone.
We may see a wide version of Samsung’s Galaxy Z Fold phone sooner rather than later, according to a report by Android Authority using Android Package files spotted by known leaker wr3ckl3ss. The latest One UI 9 build includes light and dark mode animations for a new foldable phone, which could be the wide Samsung Galaxy Z Fold.
The latest data scraped from Samsung’s One UI Android APKs has a product codename — «H8» — plastered all over it. Android Authority’s previous reporting connected the H8 to a device model number SM-F971U, which is rumored to be a wide Galaxy Z Fold phone. While data scraped from APKs doesn’t always make it to a full release of the software, the mention of new hardware is a good flag for what’s being internally developed.
It’s important to note that there are still no leaked photos or concrete visual assets indicating the existence of the wide Galaxy Z Fold. Several crude AI mockups have circulated online, generated in response to features that might show up on Samsung’s rumored phone, but no leaker has produced real photos of the device.
A representative for Samsung didn’t immediately respond to a request for comment.
Most of our knowledge about this new Galaxy Z Fold is derived from a Korean report from Etnews, which says Samsung has been working on a device referred to internally as the «Wide Fold.» While the latest info gleaned from the APKs doesn’t offer insight into how the phone will look, this report claims the Wide Fold will be squarer and boxier, with a 4:3 aspect ratio. The phone could have a 7.6-inch internal screen when open, and a 5.4-inch external display when folded, according to the report.
Samsung’s rumored wide foldable phone might be designed to shake up its lineup just as Apple is rumored to bring its first iPhone Fold to the market in 2026. It also follows the launch of Samsung’s Galaxy Z Trifold earlier this year.
The H8 animations included in the latest One UI APKs are the most compelling developments surrounding this phone we’ve seen yet, and they might lend credence to the idea that we’ll hear more about the Wide Fold through official Samsung channels soon.
-
Technologies3 года agoTech Companies Need to Be Held Accountable for Security, Experts Say
-
Technologies3 года agoBest Handheld Game Console in 2023
-
Technologies3 года agoTighten Up Your VR Game With the Best Head Straps for Quest 2
-
Technologies4 года agoBlack Friday 2021: The best deals on TVs, headphones, kitchenware, and more
-
Technologies5 лет agoGoogle to require vaccinations as Silicon Valley rethinks return-to-office policies
-
Technologies5 лет agoVerum, Wickr and Threema: next generation secured messengers
-
Technologies4 года agoOlivia Harlan Dekker for Verum Messenger
-
Technologies4 года agoiPhone 13 event: How to watch Apple’s big announcement tomorrow
